Pharmac will fund Cerazette for endometriosis treatment

Pharmac will begin funding the contraceptive pill Cerazette from April 1, 2025. This decision is significant for women with endometriosis, including Kaydi O’Connor, who has struggled with the condition for 14 years. O’Connor previously paid $50 every three months for Cerazette, which helps manage her symptoms. She has experienced severe menstrual issues, including prolonged bleeding and pain. Endometriosis affects many women, causing tissue similar to the uterus lining to grow outside the uterus. The funding of Cerazette is expected to provide relief for those managing this condition.